TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Implementation of Brief Cognitive Behavioral Therapy in CBOCs
Brief Summary: The purpose of this study is to determine the effectiveness of a brief cognitive behavioral therapy (bCBT) intervention for Veterans with depression delivered by mental health providers located at VA Community Based Outpatient Clinics (CBOC's) associated with the Houston and Oklahoma City VAMCs.


Options:
A: Arm Label: bCBT/Direct Referral; Type: EXPERIMENTAL; Interventions: Behavioral: bCBT | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: bCBT; Assigned to Arm(s): bCBT/Direct Referral
B: Arm Label: Fresh transfusion; Type: OTHER; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Arm Label: Old transfusion; Type: EXPERIMENTAL; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Intervention Type: PROCEDURE; Name: Fresh transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion | Intervention Type: PROCEDURE; Name: Old transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of 5 days or less storage age | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of conventional storage age | Intervention Type: OTHER; Name: RBC transfusion of 5 days or less storage age; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RBC transfusion of conventional storage age; Assigned to Arm(s): 2
D: Arm Label: Transfusion of PRBC stored for 1 week; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood Transfusion, Other: Packed red blood cells | Arm Label: Transfusion of PRBC stored for 2 weeks; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion, Other: Packed red blood cells | Arm Label: Transfusion of PRBC stored for 3 weeks; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion, Other: Packed red blood cells | Arm Label: Transfusion of PRBC stored for 4 weeks; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion, Other: Packed red blood cells | Arm Label: Transfusion of PRBC stored for 5 weeks; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion, Other: Packed red blood cells | Arm Label: Transfusion of PRBC stored for 6 weeks; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion, Other: Packed red blood cells | Intervention Type: PROCEDURE; Name: Blood Transfusion; Assigned to Arm(s): Transfusion of PRBC stored for 1 week, Transfusion of PRBC stored for 2 weeks, Transfusion of PRBC stored for 3 weeks, Transfusion of PRBC stored for 4 weeks, Transfusion of PRBC stored for 5 weeks, Transfusion of PRBC stored for 6 weeks | Intervention Type: OTHER; Name: Packed red blood cells; Assigned to Arm(s): Transfusion of PRBC stored for 1 week, Transfusion of PRBC stored for 2 weeks, Transfusion of PRBC stored for 3 weeks, Transfusion of PRBC stored for 4 weeks, Transfusion of PRBC stored for 5 weeks, Transfusion of PRBC stored for 6 weeks

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intervention for Diabetes With Education, Advancement and Support (IDEAS) Study
Brief Summary: This study aims to evaluate a culturally appropriate, low cost and sustainable management plan for patients with type 2 diabetes mellitus (T2DM). Various randomized controlled trials confirmed that T2DM can be delayed with lifestyle intervention and programmes which promote improvements in diet, increased physical activity and weight loss. Translation of lifestyle intervention to real-life settings however remains a major challenge.

The investigators therefore propose a diabetes management trial for T2DM patients using telemedicine. This project's innovations include the use of information technology to deliver messages to the physicians while similarly involving family members of diabetics to manage the patient's condition collectively. This creates a sense of well-being, empowering the individual as well as the community to be responsible for their own health and well-being


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Resistance Training; Assigned to Arm(s): N/A
C: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: EMPOWER-PAR Intervention; Type: EXPERIMENTAL; Interventions: Other: EMPOWER-PAR Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EMPOWER-PAR Intervention; Assigned to Arm(s): EMPOWER-PAR Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COMPASS Trial: a Direct Aspiration First Pass Technique
Brief Summary: Intravenous (IV) tissue plasminogen activator (tPA) administration has been shown to be safe and effective for treatment of AIS within 3 hours of symptom onset, and newer evidence has shown potential benefit out to 4.5 hours. Mechanical thrombectomy for AIS patients has been shown in clinical trials to be safe up to 8 hours after symptom onset. Recent trials utilizing advanced imaging to identify patients with large vessel occlusions amenable to intra-arterial thrombectomy (IAT) have shown superiority endovascular therapy over medical therapy to result in improved patient functional outcomes. Pilot data utilizing the ADAPT approach has shown superior technical results with similar functional outcomes while lowering procedure time and device costs versus traditional stent retriever as a first line therapy approaches


Options:
A: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
B: Arm Label: ADAPT Technique/Standard SR Group; Type: OTHER; Interventions: Other: Adapt/Standard Stent Retriever (SR) Group | Intervention Type: OTHER; Name: Adapt/Standard Stent Retriever (SR) Group; Assigned to Arm(s): ADAPT Technique/Standard SR Group
C: Arm Label: Combined use of contact aspiration and stent retriever; Type: EXPERIMENTAL; Interventions: Combination Product: Combined contact aspiration/Stent Retriever Technique | Arm Label: Stent retriever mechanical thrombectomy alone; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent retriever technique | Intervention Type: COMBINATION_PRODUCT; Name: Combined contact aspiration/Stent Retriever Technique; Assigned to Arm(s): Combined use of contact aspiration and stent retriever | Intervention Type: DEVICE; Name: Stent retriever technique; Assigned to Arm(s): Stent retriever mechanical thrombectomy alone
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients
Brief Summary: The purpose of this study is to determine whether Gum Arabic is effective as fetal hemoglobin inducing agent for sickle cell anemia patients.


Options:
A: Arm Label: Broccoli sprout homogenate ingestion; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Broccosprouts® (Brassica Protection Products LLC) homogenate | Intervention Type: DIETARY_SUPPLEMENT; Name: Broccosprouts® (Brassica Protection Products LLC) homogenate; Assigned to Arm(s): Broccoli sprout homogenate ingestion
B: Arm Label: Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intrevention arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Gum Arabic | Intervention Type: DIETARY_SUPPLEMENT; Name: Gum Arabic; Assigned to Arm(s): Intrevention arm
D: Arm Label: Cannabis; Type: EXPERIMENTAL; Interventions: Drug: Cannabis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cannabis | Intervention Type: DRUG; Name: Cannabis; Assigned to Arm(s): Cannabis, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure
Brief Summary: A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.


Options:
A: Arm Label: Auto-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Auto-hMSCs | Arm Label: Allo-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Allo-hMSCs | Intervention Type: BIOLOGICAL; Name: Auto-hMSCs; Assigned to Arm(s): Auto-hMSCs | Intervention Type: BIOLOGICAL; Name: Allo-hMSCs; Assigned to Arm(s): Allo-hMSCs
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous human mesenchymal cells (hMSCs) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous human bone marrow cells (hBMCs) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Autologous human mesenchymal cells (hMSCs); Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Autologous human bone marrow cells (hBMCs); Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Sham, no injection | Arm Label: C3BS-CQR-1 Treated; Type: EXPERIMENTAL; Interventions: Biological: Injection of C3BS-CQR-1 | Intervention Type: BIOLOGICAL; Name: Injection of C3BS-CQR-1; Assigned to Arm(s): C3BS-CQR-1 Treated | Intervention Type: BIOLOGICAL; Name: Sham, no injection; Assigned to Arm(s): Control
D: Arm Label: Experimental: Human (aMBMC); Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) | Arm Label: Placebo:Lactated Ringer's Solution (LRS); Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactated Ringer's Solution | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC); Assigned to Arm(s): Experimental: Human (aMBMC) | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): Placebo:Lactated Ringer's Solution (LRS)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)
Brief Summary: Stress ulcer prophylaxis (SUP) is standard of care in the intensive care unit (ICU), however the quantity and quality of evidence is low and potential harm has been reported.

The aim of the SUP-ICU trial is to asses the overall benefits and harms of SUP with proton pump inhibitor in adult critically ill patients in the ICU.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole 20 mg daily | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: famotidine 40 mg daily | Intervention Type: DRUG; Name: esomeprazole 20 mg daily; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: famotidine 40 mg daily; Assigned to Arm(s): 2
B: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A
C: Arm Label: Proton pump inhibitor (PPI); Type: EXPERIMENTAL; Interventions: Drug: Pantoprazole | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (0.9%) | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Proton pump inhibitor (PPI) | Intervention Type: OTHER; Name: Saline (0.9%); Assigned to Arm(s): Normal saline
D: Intervention Type: DRUG; Name: Esomeprazole Sodium; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Brief Summary: A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and tolerability of APL-130277.


Options:
A: Arm Label: APL-130277; Type: EXPERIMENTAL; Interventions: Drug: APL-130277 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: APL-130277; Assigned to Arm(s): APL-130277 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Behavioral: No Intervention | Arm Label: Vigorous Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Vigorous Exercise | Arm Label: Moderate Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Exercise | Intervention Type: BEHAVIORAL; Name: Moderate Exercise; Assigned to Arm(s): Moderate Exercise | Intervention Type: BEHAVIORAL; Name: Vigorous Exercise; Assigned to Arm(s): Vigorous Exercise | Intervention Type: BEHAVIORAL; Name: No Intervention; Assigned to Arm(s): Control Group
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3, Dietary Supplement: calcium | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium, Other: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Arm 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2
D: Arm Label: Physical Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of the Immediately Postpartum Insertion of the Etonogestrel Releasing Implant on Infant Growth and Development
Brief Summary: This study aims to assess whether there is change in the growth and development of newborns whose mothers will have a etonogestrel (ENG) releasing implant inserted in the first 24 to 48 hours of delivery compared with those with standard implant insertion (6 week postpartum).


Options:
A: Arm Label: PostPlacental IUD insertion; Type: EXPERIMENTAL; Interventions: Device: Copper T intrauterine device | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Copper T intrauterine device; Assigned to Arm(s): PostPlacental IUD insertion
B: Arm Label: early insertion; Type: EXPERIMENTAL; Interventions: Drug: early insertion | Arm Label: conventional insertion; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional insertion | Intervention Type: DRUG; Name: early insertion; Assigned to Arm(s): early insertion | Intervention Type: DRUG; Name: conventional insertion; Assigned to Arm(s): conventional insertion
C: Arm Label: Levonorgestrel (LNG) implants immediately postpartum; Type: ACTIVE_COMPARATOR; Interventions: Device: Jadelle | Arm Label: Levonorgestrel (LNG) implants 6 weeks postpartum; Type: ACTIVE_COMPARATOR; Interventions: Device: Jadelle | Intervention Type: DEVICE; Name: Jadelle; Assigned to Arm(s): Levonorgestrel (LNG) implants immediately postpartum | Intervention Type: DEVICE; Name: Jadelle; Assigned to Arm(s): Levonorgestrel (LNG) implants 6 weeks postpartum
D: Arm Label: Interval IUD Placement; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Immediate Postplacental IUD placement; Type: EXPERIMENTAL; Interventions: Device: Immediate Postplacental Placement of an IUD during cesarean delivery | Intervention Type: DEVICE; Name: Immediate Postplacental Placement of an IUD during cesarean delivery; Assigned to Arm(s): Immediate Postplacental IUD placement

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel \[C/P\]) and continued as maintenance therapy compared with chemotherapy alone.


Options:
A: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
B: Arm Label: Placebo + Carboplatin + Paclitaxel -> Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Placebo; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Veliparib; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: OTHER; Name: Placebo to Veliparib; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo
C: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cervical Pessary vs. Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial
Brief Summary: The purpose of this randomized control trial is to determine whether cervical pessary plus vaginal progesterone is superior to vaginal progesterone alone in decreasing preterm delivery rate, and improving perinatal outcome, among women presenting with an asymptomatic mid-pregnancy short cervix, in singleton and twin gestations.

All women with singleton or twin pregnancies undergoing routine ultrasonography up to 24 completed weeks of gestation (for examination of fetal anatomy and growth) and diagnosed with cervical length of ≤25 mm in singleton, or ≤38 mm in twins, will be invited to participate in the clinical trial.

Women who meet eligible criteria will be invited to participate in the clinical trial.

Women will be randomly assigned into one of the following groups: group A (vaginal progesterone) or group B (vaginal progesterone + pessary).

Follow-up visits for ultrasound assessment of fetal growth and cervical length will be carried out every two weeks until 37 weeks of gestation.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Silicon ring (Arabin Pessary) | Intervention Type: DEVICE; Name: Silicon ring (Arabin Pessary); Assigned to Arm(s): 2
B: Arm Label: Intravaginal progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prometrium | Arm Label: Intravaginal progesterone and pessary; Type: EXPERIMENTAL; Interventions: Drug: Prometrium, Device: Dr. Arabin, cerclage pessary perforated | Intervention Type: DRUG; Name: Prometrium; Assigned to Arm(s): Intravaginal progesterone, Intravaginal progesterone and pessary | Intervention Type: DEVICE; Name: Dr. Arabin, cerclage pessary perforated; Assigned to Arm(s): Intravaginal progesterone and pessary
C: Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Arm Label: Progesterone plus Experimental device; Type: EXPERIMENTAL; Interventions: Device: Pessary | Intervention Type: DEVICE; Name: Pessary; Assigned to Arm(s): Progesterone plus Experimental device | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone
D: Arm Label: Cervical Pessary-Group; Type: EXPERIMENTAL; Interventions: Device: cervical pessary | Arm Label: Control-Group; Type: OTHER; Interventions: Other: Control-Group | Intervention Type: DEVICE; Name: cervical pessary; Assigned to Arm(s): Cervical Pessary-Group | Intervention Type: OTHER; Name: Control-Group; Assigned to Arm(s): Control-Group

Answer: C